Mobia Medical, Inc.

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, focusing on implantable systems for stroke rehabilitation and other neurological conditions. Its main product is the Vivistim System, an FDA-approved implantable device that combines vagus nerve stimulation with therapy to help post-stroke patients improve upper limb motor function. The paired VNS platform aids patients in relearning movements and reducing motor deficits. The company is also developing the platform for additional chronic neurologic conditions such as tinnitus. Mobia Medical serves healthcare professionals, patients, and caregivers involved in stroke rehabilitation and chronic neurological care.

Mobia Medical, Inc. is listed on the NasdaqGS exchange under the ticker symbol MOBI. The company trades in US Dollars (USD), as it is based in the United States. Being listed on a major US exchange like Nasdaq provides liquidity and visibility for investors interested in the healthcare and medical devices sector.

Mobia Medical operates in the Healthcare sector, specifically within the Medical Devices industry. The company focuses on neurostimulation technology, developing implantable devices that use vagus nerve stimulation to treat chronic neurological conditions. As a medical device company, it is involved in the design, development, and commercialization of therapeutic devices that require regulatory approvals, such as FDA clearance for its Vivistim System.

Mobia Medical is headquartered in Austin, Texas, United States. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. While its primary market is the United States, its products address global needs in neurological rehabilitation. The company was founded in 2007 and has since focused on developing neurostimulation therapies to improve patient outcomes.

Mobia Medical generates revenue by commercializing its neurostimulation medical devices, primarily the Vivistim System, which is an FDA-approved implantable device for stroke rehabilitation. The company sells these devices to healthcare providers and institutions that treat patients with chronic neurological conditions. Additionally, it supports its products with information and resources for healthcare professionals, patients, and caregivers. The business model involves ongoing development of the paired VNS platform for additional indications like tinnitus, which could expand its revenue streams. As a medical device company, revenue comes from device sales and potentially from associated services or consumables.